RVV Revive Therapeutics Ltd

Revive Therapeutics Ltd. (TSX VENTURE:RVV) ("Revive") announced today its
results for the three and nine months ended March 31, 2014. The unaudited
condensed interim consolidated financial statements and Management's Discussion
and Analysis for the period may be viewed on SEDAR at www.sedar.com.


Operational Highlights



--  On April 30, 2014, Revive announced that it has submitted a pre-IND
    meeting request to the US FDA for its Gout drug candidate, REV-002. 
--  On May 14, 2012, Revive announced positive pre-clinical results for Rett
    Syndrome, a rare disease. 



Financial Highlights



--  Cash and cash equivalents at March 31, 2014 totaled $1,488,307 (June 30,
    2013 - $705,865). 
--  The net loss for the three and nine months ended March 31, 2014 was
    $278,876 and $876,932, respectively (three months ended March 31, 2013 -
    loss of $29,164; period from August 7, 2012 to March 31, 2013 - loss of
    $98,665). 
--  The Company's Research costs for the three and nine months ended March
    31, 2014 were $14,543 and $37,942, respectively (three months ended
    March 31, 2013 - $10,872; period from August 7, 2012 to March 31, 2013 -
    $55,200). 



Fabio Chianelli, Chief Executive Officer of Revive Therapeutics Ltd., commented,
"I am very pleased with our clinical and regulatory progress that we have
achieved to date and our commitment to bring novel solutions for unmet medical
needs."


About Revive Therapeutics Ltd.

Revive Therapeutics Ltd. is a Canadian public company (TSX VENTURE:RVV) focused
on acquiring, developing and commercializing treatments for major market
opportunities such as gout, postoperative pain, and rare diseases. Revive aims
to bring drugs to market by finding new uses for old drugs, also known as drug
repurposing or drug repositioning, and improving the therapeutic performance of
existing drugs for underserved medical needs. Additional information on Revive
is available at www.revivethera.com.


The information in this news release includes certain information and statements
about management's view of future events, expectations, plans and prospects that
constitute forward looking statements that may not be based on historical fact,
including without limitation statements containing the words "believe", "may",
"plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and
similar expressions. These statements are based upon assumptions that are
subject to significant risks and uncertainties. Because of these risks and
uncertainties and as a result of a variety of factors, the actual results,
expectations, achievements or performance may differ materially from those
anticipated and indicated by these forward looking statements. Such factors
include, among others, Revive's stage of development, lack of any product
revenues, additional capital requirements, risk associated with the completion
of clinical trials and obtaining regulatory approval to market products, the
ability to protect intellectual property, dependence on business partners and
the prospects for negotiating joint ventures, distribution and licensing
arrangements and their timing. 

Specifically, certain risks and uncertainties that could cause such actual
events or results expressed or implied by such forward-looking statements and
information to differ materially from any future events or results expressed or
implied by such statements and information include, but are not limited to; the
risks and uncertainties that Revive may not be able to successfully develop and
obtain regulatory approval for its products; intellectual property disputes;
future operating results are uncertain and likely to fluctuate; ability to raise
additional capital; successfully establishing additional corporate
collaborations, distribution or licensing arrangements; establishing marketing
and the costs of launching products may be restricting; Revive's lack of
experience in commercial manufacturing; increased competition from
pharmaceutical and biotechnology companies; and other factors as described in
detail in Revive's filings on SEDAR (www.sedar.com), including, without
limitation, Revive's Filing Statement dated November 26, 2013 filed on SEDAR on
November 27, 2013. Given these risks and uncertainties, readers are cautioned
not to place undue reliance on such forward-looking statements and information,
which are qualified in their entirety by this cautionary statement. Although
Revive believes that the expectations reflected in forward looking statements
are reasonable, it can give no assurances that the expectations of any forward
looking statements will prove to be correct. Except as required by law, Revive
disclaims any intention and assumes no obligation to update or revise any
forward looking statements to reflect actual results, whether as a result of new
information, future events, changes in assumptions, changes in factors affecting
such forward looking statements or otherwise.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Revive Therapeutics Ltd.
Fabio Chianelli
Chief Executive Officer
905-605-5535 (ext. 10)
fabio@revivethera.com
www.revivethera.com

Revive Therapeutics (TSXV:RVV)
Historical Stock Chart
From Mar 2024 to Apr 2024

Revive Therapeutics (TSXV:RVV)
Historical Stock Chart
From Apr 2023 to Apr 2024